Cardiovascular Risk and Mild Thyroid Hormone Deficiency: Are there some

Differences in the Elderly? by Pasqualetti, Giuseppe et al.
Cardiovascular Risk and Mild Thyroid Hormone Deficiency: Are there some
Differences in the Elderly?
Giuseppe Pasqualetti1, Gennaro Pagano2,3* and Fabio Monzani1
1Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy
2Department of Medicine and Health Sciences, School of Medicine, University of Molise, Campobasso, Italy
3Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy
*Corresponding author: Fabio Monzani, MDGeriatrics Unit, Department of Clinical and Experimental Medicine, University of PisaVia Paradisa, 56100 – Pisa, Italy, Tel:
+39 050 997363; Fax: +39 050 997549; E-mail: fabio.monzani@med.unipi.it
Rec date: Sep 16, 2014, Acc date: Sep 17, 2014, Pub date: Sep 25, 2014
Copyright: © 2014 Pasqualetti, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: Elderly; Subclinical hypothyroidism; Quality of life;
Cardiovascular risk; Cardiovascular events; Heart failure; Ischemic
heart disease; Mortality
Editorial
Subclinical hypothyroidism (sHT) is a clinical condition defined as
serum TSH concentration above the upper limit of the reference range
in the face of normal free T4 (FT4) and free T3 (FT3) levels.
Subclinical hypothyroidism, the prevalence of which increases with
age, especially among women, up to almost 20%, encompasses several
pathological entities, mainly represented by chronic autoimmune
thyroiditis [1,2]. sHT is often associated to symptoms that resembles
those of overt hypothyroidism, although to a lesser extent thus, the
expression ‘mild thyroid impairment’ or ‘mild thyroid hormone
deficiency’ would be more appropriate for defining such a condition
[1]. Nonetheless, the term sHT is recognized worldwide and will be
utilized in the present editorial. Since 90s, a relationship between sHT
and increased cardio-vascular (CV) risk (both heart failure and
coronary heart disease events) has been reported, although some
experiences suggest that the risk may depend on the degree of TSH
elevation [1,3-5]. Moreover, several reports from elderly population
(>65 years old) showed that this relationship seems no longer evident
in such individuals especially in the oldest old (>85 years old) [6-9].
The relationship between thyroid function and ageing has been
hypothesized more than almost two decades ago [8]. Several clinical
studies confirmed an age-dependent decrease of thyroid function
including iodine uptake and thyroid hormone production [9].
However, it should be underlined that direct age-related changes need
to be distinguished from the actual alterations induced by thyroid
diseases or non-thyroidal illness. In this setting, conflicting results still
exist regarding the serum TSH reference range and its modification
with ageing between earlier reports (mainly case-control or cross-
sectional) and recent large naturalistic studies [3,7-8,10-14]. Given that
sHT is essentially recognized as abnormal serum TSH elevation, the
definition of a worldwide recognized age-related reference range is
clearly warranted.
Thyroid hormones (TH) are implicated in maintaining and
integrating metabolic homeostasis at multiple levels, and their
deficiency can affect CV system by complex mechanisms involving
both myocardium and vasculature, favouring hypertension and
diastolic heart alteration. Moreover, sHT is associate to atherogenic
conditions such as metabolic alterations, characterized by
hypercholesterolemia and glucose intolerance as well as impaired
coagulation [9]. These findings may explain the reported association
between thyroid hormone deficiency and increased risk of CV
diseases. However, whereas TH deficiency may contribute to
atherogenic CV alterations (e.g. increase coronary heart disease
(CHD) risk) in young adults (<65 years old) and moderate old patients
(<75 years old), data from both humans and animal models showed a
negative correlation between serum TH value and longevity [1,10]. In
this setting, conflicting data are still existing on the association
between sHT and CHD: some studies reporting increased risk
[4,11-12], some decreased [13] and some the lack of any association
[14-21]. Since inconsistent data were especially obtained in the elderly,
the risk of CHD in sHT patients has been suggested to be specific of
young adults. However, it is worth to mention that most reports did
not accurately explore the possible age-related differences in CHD risk,
even in case the elderly represented a large share of the enrolled
population.
One of the most recent prospective study by Hyland et al. on 4,863
older people (>65 years), in which thyroid status was updated with
subsequent TSH measurements, did not find any association between
persistent or transient sHT and incident CHD or CV death. Additional
analysis stratified by the degree of serum TSH elevation (4.5-6.9;
7.0-9.9 and 10.0-19.9 mIU/l) confirmed the absence of this association
[22]. Accordingly, a cross-sectional study with subgroup analyses by
age evidenced an increased CHD risk only in younger sHT
participants (<50 years old) [23]. Moreover, a meta-analysis of 5
studies demonstrated that sHT is associated with increased CHD
prevalence and events only in young adults (aged <65 years), in which
an increased incidence of CHD was present regardless the degree of
serum TSH elevation [24]. Interestingly, one of the most interesting
study on in the oldest old population (>85 years) suggested that high
levels of TSH not only do not exert adverse effects but also may favor a
prolonged lifespan [7]. However, in a large prospective study on 1,587
community-dwelling older men, the association between sHT and CV
events or total mortality has been obtained independently from TSH
elevation (TSH above 10.0 mIU/l was detected only in 8 men) [25]. At
partially odds, a very large, recent meta-analysis clearly showed that, in
age- and sex-adjusted analyses, the risk of CHD events and mortality
increases with rising serum TSH level, reaching the statistical
significance only in patients with TSH values above 10 mIU/l
regardless of patients’ age [26].
Overall the negative effect of sHT on CHD events and mortality
appears well established in subjects younger than 65 years but less
evident in older people or no present in the oldest old population.
However, the inconsistency in results among studies in elderly patients
might be due also to the duration of tissue exposure to sHT or of
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follow-up, as well as to the presence or not of comorbidity (pre-existing
cardiovascular or other chronic diseases).
Another possible explanation of the positive association between
sHT and longevity in the oldest old subjects could be that oldest old
people is a genetically selected population with a reduced risk of CV
diseases. In any case, to shed more light on this aspect large,
randomized, prospective studies are warranted to assess whether sHT
actually affects CV disease progression and events in older people,
analyzing results according to the age groups of participants.
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